FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF

Stock Down By 79.9%

 
• By Ayisha Sharma

Months after a disappointment in Duchenne muscular dystrophy, the US firm’s pamrevlumab has missed the mark in a pivotal idiopathic pulmonary fibrosis trial, boding poorly for other trials and forcing the firm to enter cost-cutting mode.  

hand throwing ball of paper into wastebasket
FibroGen Is Scrapping Another Phase III Trial In IPF After The Failure • Source: Shutterstock
Key Takeaways:

  • Pamrevlumab missed the primary endpoint of change in forced vital capacity versus placebo.

  • Analysts said an upcoming Duchenne muscular dystrophy readout had little chance of success.

  • FibroGen will implement cost-cutting measures to extend its runway through 2026.

FibroGen, Inc

FibroGen said it would terminate a second ongoing Phase III trial in the same indication – ZEPHYRUS-2 – as the firm’s stock price plummeted by 79.9% on the NASDAQ to $3.20 in response to the news on 26 June

More from Clinical Trials

More from R&D